UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Clinical cancer research, 2019-07, Vol.25 (13), p.3753-3758

2019

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

Clinical cancer research, 2021-09, Vol.27 (17), p.4685-4689

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

Clinical cancer research, 2015-12, Vol.21 (23), p.5205-5208

2015

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Ramucirumab for Gastric Cancer

Clinical cancer research, 2015-08, Vol.21 (15), p.3372-3376

2015

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: TAS-102

Clinical cancer research, 2017-06, Vol.23 (12), p.2924-2927

2017

Link zum Volltext

Verfügbarkeit prüfen

FDA's Approval of the First Biosimilar to Bevacizumab

Clinical cancer research, 2018-09, Vol.24 (18), p.4365-4370

2018

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Clinical cancer research, 2021-04, Vol.27 (7), p.1836-1841

2021

Link zum Volltext

Verfügbarkeit prüfen

Tissue-Agnostic Drug Development: A New Path to Drug Approval

Cancer discovery, 2021-09, Vol.11 (9), p.2139-2144

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical cancer research, 2021-09, Vol.27 (17), p.4680-4684

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical cancer research, 2022-07, Vol.28 (13), p.2733-2737

2022

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

Clinical cancer research, 2023-11, Vol.29 (21), p.4326

2023

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical cancer research, 2024-01, Vol.30 (2), p.269

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical cancer research, 2023-03, Vol.29 (5), p.838-842

2023

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical cancer research, 2022-12, Vol.28 (24), p.5244-OF5

2022

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical cancer research, 2023-06, Vol.29 (11), p.2020-2024

2023

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical cancer research, 2023-10, Vol.29 (20), p.4027

2023

Link zum Volltext

Verfügbarkeit prüfen

FDA's Approach to Regulating Biosimilars

Clinical cancer research, 2017-04, Vol.23 (8), p.1882-1885

2017

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical cancer research, 2023-09, Vol.29 (18), p.3573

2023

Link zum Volltext

Verfügbarkeit prüfen

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical cancer research, 2021-11, Vol.27 (21), p.5753-5756

2021

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Clinical cancer research, 2010-09, Vol.16 (17), p.4331-4338

2010

Link zum Volltext

Verfügbarkeit prüfen

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical cancer research, 2021-10, Vol.27 (19), p.5161-5167

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

Current oncology reports, 2020-11, Vol.22 (11), p.116-116, Article 116

2020

Link zum Volltext

Verfügbarkeit prüfen

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a Physician's Choice Control Arm in a Randomized Approval Trial

Clinical cancer research, 2012-03, Vol.18 (6), p.1496-1505

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(48)
Buchkapitel
(1)

Sprache

Englisch
(49)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Oncology
(28)
Humans
(26)
Adult
(13)
United States
(13)
Drug Approval
(12)
United States Food And Drug Administration
(11)
Female
(9)
Male
(9)
Cancer Research
(7)
Middle Aged
(7)
Aged
(6)
Antineoplastic Agents - Therapeutic Use
(6)
Biological And Medical Sciences
(5)
Neoplasms - Drug Therapy
(5)
Disease-Free Survival
(4)
Medical Sciences
(4)
Randomized Controlled Trials As Topic
(4)
Antibodies, Monoclonal, Humanized
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

FDA Approval Summary: Ramucirumab for Gastric Cancer

FDA Approval Summary: TAS-102

FDA's Approval of the First Biosimilar to Bevacizumab

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Tissue-Agnostic Drug Development: A New Path to Drug Approval

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

FDA's Approach to Regulating Biosimilars

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a Physician's Choice Control Arm in a Randomized Approval Trial

Suchergebnisse filtern